Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk
- PMID: 32508330
- PMCID: PMC7458533
- DOI: 10.3233/JPD-201965
Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk
Abstract
There is growing recognition in the field of neurodegenerative diseases that mixed proteinopathies are occurring at greater frequency than originally thought. This is particularly true for three amyloid proteins defining most of these neurological disorders, amyloid-beta (Aβ), tau, and alpha-synuclein (αSyn). The co-existence and often co-localization of aggregated forms of these proteins has led to the emergence of concepts positing molecular interactions and cross-seeding between Aβ, tau, and αSyn aggregates. Amongst this trio, αSyn has received particular attention in this context during recent years due to its ability to modulate Aβ and tau aggregation in vivo, to interact at a molecular level with Aβ and tau in vivo and to cross-seed tau in mice. Here we provide a comprehensive, critical, and accessible review about the expression, role and nature of endogenous soluble αSyn oligomers because of recent developments in the understanding of αSyn multimerization, misfolding, aggregation, cross-talk, spreading and cross-seeding in neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, and Huntington's disease. We will also discuss our current understanding about the relative toxicity of endogenous αSyn oligomers in vivo and in vitro, and introduce potential opportunities to counter their deleterious effects.
Keywords: Amyloid-β; aggregation; cross-seeding; cross-talk; multimer; neurodegenerative disease; oligomer; tau; α-synuclein.
Conflict of interest statement
The authors have no conflict of interest to report.
Figures
Similar articles
-
The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics.Int J Mol Sci. 2023 Jun 17;24(12):10215. doi: 10.3390/ijms241210215. Int J Mol Sci. 2023. PMID: 37373401 Free PMC article. Review.
-
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.Prog Neurobiol. 2022 Jul;214:102270. doi: 10.1016/j.pneurobio.2022.102270. Epub 2022 Apr 18. Prog Neurobiol. 2022. PMID: 35447272 Review.
-
De novo designed protein inhibitors of amyloid aggregation and seeding.Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2206240119. doi: 10.1073/pnas.2206240119. Epub 2022 Aug 15. Proc Natl Acad Sci U S A. 2022. PMID: 35969734 Free PMC article.
-
14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.J Neurosci. 2018 Sep 19;38(38):8211-8232. doi: 10.1523/JNEUROSCI.1134-18.2018. Epub 2018 Aug 9. J Neurosci. 2018. PMID: 30093536 Free PMC article.
-
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro.Molecules. 2020 Jan 29;25(3):580. doi: 10.3390/molecules25030580. Molecules. 2020. PMID: 32013170 Free PMC article.
Cited by
-
Pathological and physiological functional cross-talks of α-synuclein and tau in the central nervous system.Neural Regen Res. 2024 Apr;19(4):855-862. doi: 10.4103/1673-5374.382231. Neural Regen Res. 2024. PMID: 37843221 Free PMC article. Review.
-
Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases.Nat Rev Chem. 2021 Apr;5(4):277-294. doi: 10.1038/s41570-021-00254-9. Epub 2021 Feb 15. Nat Rev Chem. 2021. PMID: 37117282 Review.
-
Oligomerization by co-assembly of β-amyloid and α-synuclein.Front Mol Biosci. 2023 Mar 20;10:1153839. doi: 10.3389/fmolb.2023.1153839. eCollection 2023. Front Mol Biosci. 2023. PMID: 37021111 Free PMC article. Review.
-
Structural and dynamic insights into α-synuclein dimer conformations.Structure. 2023 Apr 6;31(4):411-423.e6. doi: 10.1016/j.str.2023.01.011. Epub 2023 Feb 20. Structure. 2023. PMID: 36809765
-
Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications.Pharmacol Rev. 2023 Mar;75(2):263-308. doi: 10.1124/pharmrev.122.000654. Epub 2022 Dec 22. Pharmacol Rev. 2023. PMID: 36549866 Free PMC article. Review.
References
-
- Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10, S10–S17. - PubMed
-
- Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM-Y, Trojanowski JQ (2018) Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain 141, 2181–2193. - PMC - PubMed
-
- Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH, Brownstein MJ, Tagle DA (2000) Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington’s disease patients and transgenic mouse models. Neurosci Lett 289, 29–32. - PubMed
-
- Tomás-Zapico C, Díez-Zaera M, Ferrer I, Gómez-Ramos P, Morán MA, Miras-Portugal MT, Díaz-Hernández M, Lucas JJ (2012) α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington’s disease. Hum Mol Genet 21, 495–510. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
